**Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia**

Vasily Isakov, Igor Nikitin, Vladimir Chulanov, Pavel Ogurtsov, Ekaterina Lukyanova, Jianmin Long, Janice Wahl, Frans A Helmond, for the P08160 Trial Investigators

**Supplementary Table 1** **Comparison of virologic response rates between Russian patients and western patients receiving boceprevir-based triple therapy in the SPRINT-2 and RESPOND-2 studies**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Russian Patients | SPRINT-2 | RESPOND-2 |
|  | BOC RGT | PR | BOC RGT | PR | BOC RGT | PR |
| TN |  |  |  |  |  |  |
|  EOT | 89/97 (91.8) | 33/48 (68.8) | 277/366 (76) | 191/363 (53) | — | — |
|  SVR | 76/97 (78.4) | 27/48 (56.3) | 242/366 (66) | 137/363 (38) | — | — |
|  Relapse | 13/89 (14.6) | 6/33 (18.2) | 24/265 (9) | 39/176 (22) | — | — |
| TE |  |  |  |  |  |  |
|  EOT | 50/62 (80.6) | 13/30 (43.3) | — | — | 114/162 (70.4) | 25/80 (31) |
|  SVR | 43/62 (69.4) | 9/30 (30) | — | — | 107/161 (66) | 17/80 (21) |
|  Relapse | 7/48 (14.6) | 3/12 (25.0) | — | — | 14/121 (12) | 8/25 (32) |

BOC: boceprevir; EOT: end of treatment response; PR: peginterferon/ribavirin; RESPOND-2: Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 study; RGT: response-guided therapy; SPRINT-2: Serine Protease Inhibitor Therapy 2 study; SVR: sustained virologic response; TE: treatment experienced; TN: treatment naive.